drugset / Trial / NCT03031119

Multiple Ascending Dose and DDI Study

NCT03031119

Phase 1 Completed 62 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

Part A will investigate the safety, tolerability, PK and PD of PF-06835919 administered for 14 days in a multiple ascending dose design. Part B will assess the effect of PF-06835919 co-administration at low and high doses on the PK of atorvastatin in a single cohort.

Timeline

Start
2017-01
Primary completion
2017-07
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule
Subject PF-06835919 Small molecule

Indications

No indication recorded.